FROM THE TEAM
Homework: Who's Responsible - Teacher or Student?
A great deal has been made about the Drug System Renewal Forum in Ontario that got underway in the summer, and the recently announced changes in Alberta. There is hope in Ontario that the provincial government will extend the same lower drug prices it has secured within its public programs to all Ontarians regardless of coverage. The hype out of Alberta is that they have announced that new lower prices on generic drugs will apply across the board, and not just to the public sector. The limitation in Wild Rose Country is that the announced reduction of generic drug prices to 45% of the brand price will only apply to new generics entering the market. There is no word on what will happen with existing generic drug prices. On the brand drug side, the Alberta government has announced changes will be occurring, but have provided no details as to what they will be. So it is difficult to determine what the impact will be for private plan sponsors.
In Ontario, the picture is even more abstract, and the situation was certainly not assisted with the Minister of Health getting run out of office with the eHealth scandal. The one thing that was clear from the meetings this summer is that any changes to drug pricing outside of the public sector is far from certain.
The problem is that many stakeholders within the provision of drug plan benefits in the private sector seem content to sit back and let their respective provincial governments swoop in and solve some of the challenges that exist in containing plan costs. In our view, that's like expecting the teacher to do your homework for you.
Any student that wants to get ahead is going to make him/herself responsible for their own education. Students looking to distinguish themselves will go well past the minimum, and take the initiative to move forward on their own - regardless of what the rest of the class is doing. Plan sponsors who choose to wait and see how provincial governments across the country will assist in cost containment are losing out on opportunities to contain plan costs immediately and in the near-term.
At the same time, something we in the private sector have yet to embrace universally is the idea that if we go above and beyond the minimum standards, and take the initiative to innovate and take charge of our own cost containment responsibilities - to be leaders and not followers of the government policies de jour - then just maybe the teacher will have more time for us when we do come across homework questions we need help with.
To pass along any comments on Cubic Health Monthly, or to see back issues of our publication, please visit our website at http://www.cubichealth.ca
Sincerely,

Mike Sullivan
President
| LATEST NEWS |
Potential "Indication Creep" for Pradax®
Pradax® (dabigatran) was the first orally administered direct thrombin inhibitor on the Canadian market when it received its NOC from Health Canada last summer. The agents in this drug class are blood thinners (anticoagulants), designed to treat or prevent clots. Currently, Pradax® is limited to use in the prevention of clots in patients who have had hip or knee surgery. It is used for this indication instead of more expensive, and more difficult to administer, heparin injections. However, with the release of the Randomized Evaluation of Long-Tern Anticoagulation Therapy (RE-LY) trial, the exclusive short-term use of this agent is likely to change.
Click here to read more...
|
| FOR THE PLAN SPONSOR |
An Update on What's Happening in Ontario & Alberta
There has been a great deal of press given to the Drug System Renewal Forum in Ontario and the changes announced by the Government of Alberta. However, when we distil what has actually taken place - there have been very few concrete developments. There has been a great deal of talk but very little action, so there is not much new for plan sponsors to concern themselves with. In Ontario's case, the timelines for announcing changes have been impacted by the unexpected resignation of the Minister of Health, David Caplan, following the scandal that has emerged within the eHealth program. In Alberta, the announcements in late October were overshadowed by a lack of details on many of the key areas that were brought forward as action items within Phase 2 of the province's Pharmaceutical Strategy.
Click here to read more...
|
|